Type 2 Diabetes

The dual SGLT1/SGLT2 inhibitor sotagliflozin is effective at reducing risk for heart failure, myocardial infarction and stroke while also slowing progression of chronic kidney disease, according to findings from two large clinical trials.

Recent data showed that add-on proton pump inhibitor therapy was associated with a significant decrease in HbA1c and fasting blood glucose. However, it did not reduce the risk for incident diabetes.

Data from the SURPASS clinical trial program suggest the dual incretin agonist tirzepatide could be a game-changing new therapy for adults with type 2 diabetes, many of whom experienced substantial weight loss and achieved normoglycemia.

A novel GLP-1 receptor agonist reduced cardiovascular event risk by 27% and kidney disease progression by 32% compared with placebo for high-risk adults with type 2 diabetes, with or without background SGLT2 inhibitor therapy, data show.

In this video exclusive, Richard E. Pratley, MD, the Samuel E. Crockett chair in diabetes research and medical director of AdventHealth Diabetes Institute, announces results from the AMPLITUDE-O cardiovascular outcomes study of the exendin-based GLP-1 receptor agonist efpeglenatide.

Children with type 2 diabetes with a parental — particularly, maternal — history of diabetes have elevated risks for adverse outcomes and early onset of complications, according to a speaker.

An algorithm-based, personalized diet based on gut microbiome features and clinical data may improve glycemic response and other metabolic parameters for adults with newly diagnosed type 2 diabetes, data show.

For Jens J. Holst, MD, DMSc, there were long years spent “in the desert” studying how incretin hormones in the gut work before he and his team would go on to discover the peptide that would change type 2 diabetes and obesity management.

In a multiethnic genome study of response to diabetes drugs, researchers identified an African-ancestry genetic variant associated with favorable insulin response to metformin, according to a speaker.

Superior weight-loss efficacy with the GLP-1 receptor agonist semaglutide demonstrated in the phase 3 STEP studies suggests clinicians have a new opportunity to control obesity and its medical complications, including type 2 diabetes.